In addition to the six epigenetic drugs already approved for clinical use [41], multiple cancers have shown success with epigenetic therapy (NCT01752933, NCT01261312, NCT03189914), including histone deacetylase inhibitors and PI3K inhibitors for Myc-driven MBs [42]. Here, MYC is linked to Mobius syndrome.